Archigen Biotech Limited
Quick facts
Phase 3 pipeline
- SAIT101 · Immunology
SAIT101 is a small molecule that targets the S1P1 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: